Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors.

Fidanze SD, Liu D, Mantei RA, Hasvold LA, Pratt JK, Sheppard GS, Wang L, Holms JH, Dai Y, Aguirre A, Bogdan A, Dietrich JD, Marjanovic J, Park CH, Hutchins CW, Lin X, Bui MH, Huang X, Wilcox D, Li L, Wang R, Kovar P, Magoc TJ, Rajaraman G, Albert DH, Shen Y, Kati WM, McDaniel KF.

Bioorg Med Chem Lett. 2018 Jun 1;28(10):1804-1810. doi: 10.1016/j.bmcl.2018.04.020. Epub 2018 Apr 11.

PMID:
29678460
2.

Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).

Wagner R, Randolph JT, Patel SV, Nelson L, Matulenko MA, Keddy R, Pratt JK, Liu D, Krueger AC, Donner PL, Hutchinson DK, Flentge C, Betebenner D, Rockway T, Maring CJ, Ng TI, Krishnan P, Pilot-Matias T, Collins C, Panchal N, Reisch T, Dekhtyar T, Mondal R, Stolarik DF, Gao Y, Gao W, Beno DA, Kati WM.

J Med Chem. 2018 May 10;61(9):4052-4066. doi: 10.1021/acs.jmedchem.8b00082. Epub 2018 Apr 23.

PMID:
29653491
3.

Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability.

Randolph JT, Krueger AC, Donner PL, Pratt JK, Liu D, Motter CE, Rockway TW, Tufano MD, Wagner R, Lim HB, Beyer JM, Mondal R, Panchal NS, Colletti L, Liu Y, Koev G, Kati WM, Hernandez LE, Beno DWA, Longenecker KL, Stewart KD, Dumas EO, Molla A, Maring CJ.

J Med Chem. 2018 Feb 8;61(3):1153-1163. doi: 10.1021/acs.jmedchem.7b01630. Epub 2018 Jan 25.

PMID:
29342358
4.

Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.

McDaniel KF, Wang L, Soltwedel T, Fidanze SD, Hasvold LA, Liu D, Mantei RA, Pratt JK, Sheppard GS, Bui MH, Faivre EJ, Huang X, Li L, Lin X, Wang R, Warder SE, Wilcox D, Albert DH, Magoc TJ, Rajaraman G, Park CH, Hutchins CW, Shen JJ, Edalji RP, Sun CC, Martin R, Gao W, Wong S, Fang G, Elmore SW, Shen Y, Kati WM.

J Med Chem. 2017 Oct 26;60(20):8369-8384. doi: 10.1021/acs.jmedchem.7b00746. Epub 2017 Oct 12.

PMID:
28949521
5.

Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors.

Lam LT, Lin X, Faivre EJ, Yang Z, Huang X, Wilcox DM, Bellin RJ, Jin S, Tahir SK, Mitten M, Magoc T, Bhathena A, Kati WM, Albert DH, Shen Y, Uziel T.

Mol Cancer Ther. 2017 Aug;16(8):1511-1520. doi: 10.1158/1535-7163.MCT-16-0459. Epub 2017 May 3.

6.

Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies.

Bui MH, Lin X, Albert DH, Li L, Lam LT, Faivre EJ, Warder SE, Huang X, Wilcox D, Donawho CK, Sheppard GS, Wang L, Fidanze S, Pratt JK, Liu D, Hasvold L, Uziel T, Lu X, Kohlhapp F, Fang G, Elmore SW, Rosenberg SH, McDaniel KF, Kati WM, Shen Y.

Cancer Res. 2017 Jun 1;77(11):2976-2989. doi: 10.1158/0008-5472.CAN-16-1793. Epub 2017 Apr 17.

7.

Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors.

Wang L, Pratt JK, Soltwedel T, Sheppard GS, Fidanze SD, Liu D, Hasvold LA, Mantei RA, Holms JH, McClellan WJ, Wendt MD, Wada C, Frey R, Hansen TM, Hubbard R, Park CH, Li L, Magoc TJ, Albert DH, Lin X, Warder SE, Kovar P, Huang X, Wilcox D, Wang R, Rajaraman G, Petros AM, Hutchins CW, Panchal SC, Sun C, Elmore SW, Shen Y, Kati WM, McDaniel KF.

J Med Chem. 2017 May 11;60(9):3828-3850. doi: 10.1021/acs.jmedchem.7b00017. Epub 2017 Apr 21.

PMID:
28368119
8.

Methylpyrrole inhibitors of BET bromodomains.

Hasvold LA, Sheppard GS, Wang L, Fidanze SD, Liu D, Pratt JK, Mantei RA, Wada CK, Hubbard R, Shen Y, Lin X, Huang X, Warder SE, Wilcox D, Li L, Buchanan FG, Smithee L, Albert DH, Magoc TJ, Park CH, Petros AM, Panchal SC, Sun C, Kovar P, Soni NB, Elmore SW, Kati WM, McDaniel KF.

Bioorg Med Chem Lett. 2017 May 15;27(10):2225-2233. doi: 10.1016/j.bmcl.2017.02.057. Epub 2017 Feb 24.

PMID:
28268136
9.

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.

Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, Reisch T, Lu L, Dekhtyar T, Irvin M, Tripathi R, Maring C, Randolph JT, Wagner R, Collins C.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02558-16. doi: 10.1128/AAC.02558-16. Print 2017 May.

10.

HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues.

Lin X, Huang X, Uziel T, Hessler P, Albert DH, Roberts-Rapp LA, McDaniel KF, Kati WM, Shen Y.

Mol Cancer Ther. 2017 Feb;16(2):388-396. doi: 10.1158/1535-7163.MCT-16-0475. Epub 2016 Nov 30.

11.

Discovery of fluorobenzimidazole HCV NS5A inhibitors.

Randolph JT, Flentge CA, Donner P, Rockway TW, Patel SV, Nelson L, Hutchinson DK, Mondal R, Mistry N, Reisch T, Dekhtyar T, Krishnan P, Pilot-Matias T, Stolarik DF, Beno DWA, Wagner R, Maring C, Kati WM.

Bioorg Med Chem Lett. 2016 Nov 15;26(22):5462-5467. doi: 10.1016/j.bmcl.2016.10.030. Epub 2016 Oct 13.

PMID:
27780635
12.

Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.

Faivre EJ, Wilcox D, Lin X, Hessler P, Torrent M, He W, Uziel T, Albert DH, McDaniel K, Kati W, Shen Y.

Mol Cancer Res. 2017 Jan;15(1):35-44. doi: 10.1158/1541-7786.MCR-16-0221. Epub 2016 Oct 5.

13.

In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.

Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, Reisch T, Mondal R, Wagner R, Molla A, Maring C, Collins C.

Antimicrob Agents Chemother. 2015 Mar;59(3):1505-11. doi: 10.1128/AAC.04619-14. Epub 2014 Dec 22.

14.

In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.

Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, Kati W, Campbell A, Williams L, Xie W, Setze C, Molla A, Collins C, Pilot-Matias T.

Antimicrob Agents Chemother. 2015 Feb;59(2):979-87. doi: 10.1128/AAC.04226-14. Epub 2014 Dec 1.

15.

Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.

DeGoey DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, Krueger AC, Matulenko M, Patel S, Motter CE, Nelson L, Keddy R, Tufano M, Caspi DD, Krishnan P, Mistry N, Koev G, Reisch TJ, Mondal R, Pilot-Matias T, Gao Y, Beno DW, Maring CJ, Molla A, Dumas E, Campbell A, Williams L, Collins C, Wagner R, Kati WM.

J Med Chem. 2014 Mar 13;57(5):2047-57. doi: 10.1021/jm401398x. Epub 2014 Jan 15.

PMID:
24400777
16.

High potency improvements to weak aryl uracil HCV polymerase inhibitor leads.

Donner P, Randolph JT, Huang P, Wagner R, Maring C, Lim BH, Colletti L, Liu Y, Mondal R, Beyer J, Koev G, Marsh K, Beno D, Longenecker K, Pilot-Matias T, Kati W, Molla A, Kempf D.

Bioorg Med Chem Lett. 2013 Aug 1;23(15):4367-9. doi: 10.1016/j.bmcl.2013.05.078. Epub 2013 Jun 4.

PMID:
23791079
17.

Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif.

Krueger AC, Randolph JT, DeGoey DA, Donner PL, Flentge CA, Hutchinson DK, Liu D, Motter CE, Rockway TW, Wagner R, Beno DW, Koev G, Lim HB, Beyer JM, Mondal R, Liu Y, Kati WM, Longenecker KL, Molla A, Stewart KD, Maring CJ.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3487-90. doi: 10.1016/j.bmcl.2013.04.057. Epub 2013 May 1.

PMID:
23664214
18.

Identification of aryl dihydrouracil derivatives as palm initiation site inhibitors of HCV NS5B polymerase.

Liu Y, Lim BH, Jiang WW, Flentge CA, Hutchinson DK, Madigan DL, Randolph JT, Wagner R, Maring CJ, Kati WM, Molla A.

Bioorg Med Chem Lett. 2012 Jun 1;22(11):3747-50. doi: 10.1016/j.bmcl.2012.04.017. Epub 2012 Apr 10.

PMID:
22542020
19.

Hepatitis C NS5B polymerase inhibitors: functional equivalents for the benzothiadiazine moiety.

Hutchinson DK, Flentge CA, Donner PL, Wagner R, Maring CJ, Kati WM, Liu Y, Masse SV, Middleton T, Mo H, Montgomery D, Jiang WW, Koev G, Beno DW, Stewart KD, Stoll VS, Molla A, Kempf DJ.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1876-9. doi: 10.1016/j.bmcl.2010.12.067. Epub 2011 Jan 13.

PMID:
21316235
20.

Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitors.

Randolph JT, Flentge CA, Huang PP, Hutchinson DK, Klein LL, Lim HB, Mondal R, Reisch T, Montgomery DA, Jiang WW, Masse SV, Hernandez LE, Henry RF, Liu Y, Koev G, Kati WM, Stewart KD, Beno DW, Molla A, Kempf DJ.

J Med Chem. 2009 May 28;52(10):3174-83. doi: 10.1021/jm801485z.

PMID:
19402666
21.

Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir.

DeGoey DA, Grampovnik DJ, Flosi WJ, Marsh KC, Wang XC, Klein LL, McDaniel KF, Liu Y, Long MA, Kati WM, Molla A, Kempf DJ.

J Med Chem. 2009 May 14;52(9):2964-70. doi: 10.1021/jm900080g.

PMID:
19348416
22.

2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.

Degoey DA, Grampovnik DJ, Flentge CA, Flosi WJ, Chen HJ, Yeung CM, Randolph JT, Klein LL, Dekhtyar T, Colletti L, Marsh KC, Stoll V, Mamo M, Morfitt DC, Nguyen B, Schmidt JM, Swanson SJ, Mo H, Kati WM, Molla A, Kempf DJ.

J Med Chem. 2009 Apr 23;52(8):2571-86. doi: 10.1021/jm900044w.

PMID:
19323562
23.

Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines.

Wagner R, Larson DP, Beno DW, Bosse TD, Darbyshire JF, Gao Y, Gates BD, He W, Henry RF, Hernandez LE, Hutchinson DK, Jiang WW, Kati WM, Klein LL, Koev G, Kohlbrenner W, Krueger AC, Liu J, Liu Y, Long MA, Maring CJ, Masse SV, Middleton T, Montgomery DA, Pratt JK, Stuart P, Molla A, Kempf DJ.

J Med Chem. 2009 Mar 26;52(6):1659-69. doi: 10.1021/jm8010965.

PMID:
19226162
24.

Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well.

Mondal R, Koev G, Pilot-Matias T, He Y, Ng T, Kati W, Molla A.

Antiviral Res. 2009 Apr;82(1):82-8. doi: 10.1016/j.antiviral.2008.12.012. Epub 2009 Jan 25.

PMID:
19174175
25.

Methods to measure the intracellular concentration of unlabeled compounds within cultured cells using liquid chromatography/tandem mass spectrometry.

Colletti LM, Liu Y, Koev G, Richardson PL, Chen CM, Kati W.

Anal Biochem. 2008 Dec 15;383(2):186-93. doi: 10.1016/j.ab.2008.08.012. Epub 2008 Aug 22.

PMID:
18790690
26.

Hepatitis C NS5B polymerase inhibitors: 4,4-Dialkyl-1-hydroxy-3-oxo-3,4-dihydronaphthalene-3-yl benzothiadiazine derivatives.

Hutchinson DK, Rosenberg T, Klein LL, Bosse TD, Larson DP, He W, Jiang WW, Kati WM, Kohlbrenner WE, Liu Y, Masse SV, Middleton T, Molla A, Montgomery DA, Beno DW, Stewart KD, Stoll VS, Kempf DJ.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):3887-90. doi: 10.1016/j.bmcl.2008.06.043. Epub 2008 Jun 18.

PMID:
18599294
27.

Identification of halosalicylamide derivatives as a novel class of allosteric inhibitors of HCV NS5B polymerase.

Liu Y, Donner PL, Pratt JK, Jiang WW, Ng T, Gracias V, Baumeister S, Wiedeman PE, Traphagen L, Warrior U, Maring C, Kati WM, Djuric SW, Molla A.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3173-7. doi: 10.1016/j.bmcl.2008.04.068. Epub 2008 May 1.

PMID:
18479921
28.

Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor.

Randolph JT, Zhang X, Huang PP, Klein LL, Kurtz KA, Konstantinidis AK, He W, Kati WM, Kempf DJ.

Bioorg Med Chem Lett. 2008 Apr 15;18(8):2745-50. doi: 10.1016/j.bmcl.2008.02.053. Epub 2008 Feb 26.

PMID:
18375121
29.

Des-A-ring benzothiadiazines: inhibitors of HCV genotype 1 NS5B RNA-dependent RNA polymerase.

Donner PL, Xie Q, Pratt JK, Maring CJ, Kati W, Jiang W, Liu Y, Koev G, Masse S, Montgomery D, Molla A, Kempf DJ.

Bioorg Med Chem Lett. 2008 Apr 15;18(8):2735-8. doi: 10.1016/j.bmcl.2008.02.064. Epub 2008 Mar 4.

PMID:
18362072
30.

The emerging field of HCV drug resistance.

Koev G, Kati W.

Expert Opin Investig Drugs. 2008 Mar;17(3):303-19. doi: 10.1517/13543784.17.3.303 . Review.

PMID:
18321230
31.

Synthesis of potent pyrrolidine influenza neuraminidase inhibitors.

Krueger AC, Xu Y, Kati WM, Kempf DJ, Maring CJ, McDaniel KF, Molla A, Montgomery D, Kohlbrenner WE.

Bioorg Med Chem Lett. 2008 Mar 1;18(5):1692-5. doi: 10.1016/j.bmcl.2008.01.048. Epub 2008 Jan 18.

PMID:
18242993
32.

Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.

He Y, King MS, Kempf DJ, Lu L, Lim HB, Krishnan P, Kati W, Middleton T, Molla A.

Antimicrob Agents Chemother. 2008 Mar;52(3):1101-10. Epub 2007 Dec 17.

33.

Synthesis and SAR of novel 1,1-dialkyl-2(1H)-naphthalenones as potent HCV polymerase inhibitors.

Bosse TD, Larson DP, Wagner R, Hutchinson DK, Rockway TW, Kati WM, Liu Y, Masse S, Middleton T, Mo H, Montgomery D, Jiang W, Koev G, Kempf DJ, Molla A.

Bioorg Med Chem Lett. 2008 Jan 15;18(2):568-70. Epub 2007 Nov 28.

PMID:
18068361
34.

Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.

Chen CM, He Y, Lu L, Lim HB, Tripathi RL, Middleton T, Hernandez LE, Beno DW, Long MA, Kati WM, Bosse TD, Larson DP, Wagner R, Lanford RE, Kohlbrenner WE, Kempf DJ, Pilot-Matias TJ, Molla A.

Antimicrob Agents Chemother. 2007 Dec;51(12):4290-6. Epub 2007 Oct 1.

35.

Longer wavelength fluorescence resonance energy transfer depsipeptide substrates for hepatitis C virus NS3 protease.

Konstantinidis AK, Richardson PL, Kurtz KA, Tripathi R, Chen CM, Huang P, Randolph J, Towne D, Donnelly J, Warrior U, Middleton T, Kati WM.

Anal Biochem. 2007 Sep 15;368(2):156-67. Epub 2007 Jun 17.

PMID:
17644059
36.

A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations.

Middleton T, He Y, Pilot-Matias T, Tripathi R, Lim BH, Roth A, Chen CM, Koev G, Ng TI, Krishnan P, Pithawalla R, Mondal R, Dekhtyar T, Lu L, Mo H, Kati WM, Molla A.

J Virol Methods. 2007 Nov;145(2):137-45. Epub 2007 Jun 29.

PMID:
17604129
37.

Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of unsymmetrical 1-hydroxy-4,4-dialkyl-3-oxo-3,4-dihydronaphthalene benzothiadiazine derivatives.

Krueger AC, Madigan DL, Green BE, Hutchinson DK, Jiang WW, Kati WM, Liu Y, Maring CJ, Masse SV, McDaniel KF, Middleton TR, Mo H, Molla A, Montgomery DA, Ng TI, Kempf DJ.

Bioorg Med Chem Lett. 2007 Apr 15;17(8):2289-92. Epub 2007 Jan 27.

PMID:
17300933
38.

Mechanistic study of HCV polymerase inhibitors at individual steps of the polymerization reaction.

Liu Y, Jiang WW, Pratt J, Rockway T, Harris K, Vasavanonda S, Tripathi R, Pithawalla R, Kati WM.

Biochemistry. 2006 Sep 26;45(38):11312-23.

PMID:
16981691
39.

Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera.

Tripathi RL, Krishnan P, He Y, Middleton T, Pilot-Matias T, Chen CM, Lau DT, Lemon SM, Mo H, Kati W, Molla A.

Antiviral Res. 2007 Jan;73(1):40-9. Epub 2006 Jul 28.

PMID:
16914212
40.

A fluorescence polarization-based assay for peptidyl prolyl cis/trans isomerase cyclophilin A.

Liu Y, Jiang J, Richardson PL, Reddy RD, Johnson DD, Kati WM.

Anal Biochem. 2006 Sep 1;356(1):100-7. Epub 2006 May 12.

PMID:
16737676
41.

Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring.

Rockway TW, Zhang R, Liu D, Betebenner DA, McDaniel KF, Pratt JK, Beno D, Montgomery D, Jiang WW, Masse S, Kati WM, Middleton T, Molla A, Maring CJ, Kempf DJ.

Bioorg Med Chem Lett. 2006 Jul 15;16(14):3833-8. Epub 2006 May 2.

PMID:
16650984
42.

Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-alkyl-4-hydroxyquinolon-3-yl-benzothiadiazine sulfamides.

Krueger AC, Madigan DL, Jiang WW, Kati WM, Liu D, Liu Y, Maring CJ, Masse S, McDaniel KF, Middleton T, Mo H, Molla A, Montgomery D, Pratt JK, Rockway TW, Zhang R, Kempf DJ.

Bioorg Med Chem Lett. 2006 Jul 1;16(13):3367-70. Epub 2006 May 2.

PMID:
16650764
43.

Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors.

Randolph JT, Huang PP, Flosi WJ, DeGoey D, Klein LL, Yeung CM, Flentge C, Sun M, Zhao C, Dekhtyar T, Mo H, Colletti L, Kati W, Marsh KC, Molla A, Kempf DJ.

Bioorg Med Chem. 2006 Jun 15;14(12):4035-46. Epub 2006 Feb 28.

PMID:
16504523
44.

Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors.

Maring CJ, Stoll VS, Zhao C, Sun M, Krueger AC, Stewart KD, Madigan DL, Kati WM, Xu Y, Carrick RJ, Montgomery DA, Kempf-Grote A, Marsh KC, Molla A, Steffy KR, Sham HL, Laver WG, Gu YG, Kempf DJ, Kohlbrenner WE.

J Med Chem. 2005 Jun 16;48(12):3980-90.

PMID:
15943472
45.

Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-1-heteroalkyl-4-hydroxyquinolon-3-yl-benzothiadiazines.

Pratt JK, Donner P, McDaniel KF, Maring CJ, Kati WM, Mo H, Middleton T, Liu Y, Ng T, Xie Q, Zhang R, Montgomery D, Molla A, Kempf DJ, Kohlbrenner W.

Bioorg Med Chem Lett. 2005 Mar 15;15(6):1577-82.

PMID:
15745800
46.

Design, synthesis, and structural analysis of inhibitors of influenza neuraminidase containing a 2,3-disubstituted tetrahydrofuran-5-carboxylic acid core.

Wang GT, Wang S, Gentles R, Sowin T, Maring CJ, Kempf DJ, Kati WM, Stoll V, Stewart KD, Laver G.

Bioorg Med Chem Lett. 2005 Jan 3;15(1):125-8.

PMID:
15582424
47.

Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction.

Mo H, Konstantinidis AK, Stewart KD, Dekhtyar T, Ng T, Swift K, Matayoshi ED, Kati W, Kohlbrenner W, Molla A.

Virology. 2004 Nov 24;329(2):319-27.

48.

Inhibition of human immunodeficiency virus type I integrase by naphthamidines and 2-aminobenzimidazoles.

Middleton T, Lim HB, Montgomery D, Rockway T, Tang H, Cheng X, Lu L, Mo H, Kohlbrenner WE, Molla A, Kati WM.

Antiviral Res. 2004 Oct;64(1):35-45.

PMID:
15451177
49.

Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir.

Hickman D, Vasavanonda S, Nequist G, Colletti L, Kati WM, Bertz R, Hsu A, Kempf DJ.

Antimicrob Agents Chemother. 2004 Aug;48(8):2911-7.

50.

Hepatitis C NS3 protease inhibition by peptidyl-alpha-ketoamide inhibitors: kinetic mechanism and structure.

Liu Y, Stoll VS, Richardson PL, Saldivar A, Klaus JL, Molla A, Kohlbrenner W, Kati WM.

Arch Biochem Biophys. 2004 Jan 15;421(2):207-16.

PMID:
14984200

Supplemental Content

Support Center